A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT

Category Primary study
JournalEuropean Urology, Supplements
Year 2019
This article has no abstract
Epistemonikos ID: 14a5a6a65f4d42dc54055e57155a0c487b4a52ba
First added on: Feb 10, 2025